AccuPulse key facts
- Developer of a pulsed field ablation (PFA) system intended to treat Atrial fibrillation (A-fib).
- It has raised $64.6M; the latest was Later Stage VC ($14.5M) in Mar 2026.
- Notable investors include CICC Capital, Qianhai FoF, YuanBio Venture Capital, Leader Venture Capital, Vision Plus Capital — 10 tracked in total.
- Status: Privately Held (backing).
- ·Watch AccuPulse: the Monday email on marks, rounds and moves
AccuPulse funding rounds
No funding rounds for AccuPulse are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
AccuPulse investors
10 investors are on record for AccuPulse, including CICC Capital, Qianhai FoF, YuanBio Venture Capital and Leader Venture Capital. By type, the record holds 2 venture capital firms, 2 private equity firms and 1 fund of funds.
About AccuPulse
Developer of a pulsed field ablation (PFA) system intended to treat Atrial fibrillation (A-fib). The company's system offers a one-stop solution and system and equipment for pulse ablation of atrial fibrillation and tumors and leverages other major interventional therapies using radio frequency and cryotherapy, providing doctors and patients with a system that has better catheter localization, signal acquisition and more intelligent integration.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2020
- Website
- accupulse.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
AccuPulse doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.